Belgian biotech company Agomab Therapeutics raises €94.9M to tackle fibrosis; here's how

Ghent, Belgium-based Agomab Therapeutics, a biotech company, announced on Wednesday that it has closed a $100M (approximately €94.9M).

Related Keywords

Felice Verduyn Van Weegen ,Colleen Cuffaro ,Iyona Rajkomar ,Tim Knotnerus ,Fidelity Management Research Company ,Life Sciences ,Belgium Based Agomab Therapeutics ,Fidelity Management ,Research Company ,Dawn Biopharma ,Fibrostenosing Crohn ,Agomab Therapeutics ,Idiopathic Pulmonary Fibrosis ,Advancing Fibrosis Focused ,Chief Executive Officer ,